Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status

被引：0

作者：

Kenmotsu, H. ^{[1
]}

Iwama, E. ^{[2
]}

Goto, Y. ^{[3
]}

Harada, T. ^{[4
]}

Tsumura, S. ^{[5
]}

Sakashita, H. ^{[6
]}

Mori, Y. ^{[7
]}

Nakagaki, N. ^{[8
]}

Fujita, Y. ^{[9
]}

Seike, M. ^{[10
]}

Bessho, A. ^{[11
]}

Ono, M. ^{[12
]}

Okazaki, A. ^{[13
]}

Akamatsu, H. ^{[14
]}

Morinaga, R. ^{[15
]}

Ushijima, S. ^{[16
]}

Shimose, T. ^{[17
]}

Tokunaga, S. ^{[18
]}

Hamada, A. ^{[19
]}

Yamamoto, N. ^{[20
]}

Nakanishi, Y. ^{[2
]}

Sugio, K. ^{[21
]}

Okamoto, I. ^{[2
]}

机构：

[1] Shizuoka Canc Ctr, Shizuoka, Japan

[2] Kyushu Univ, Fukuoka, Fukuoka, Japan

[3] Natl Canc Ctr, Tokyo, Japan

[4] Jcho Kyushu Hosp, Kitakyushu, Fukuoka, Japan

[5] Kumamoto Reg Med Ctr, Kumamoto, Japan

[6] Tokyo Med & Dent Univ, Tokyo, Japan

[7] Iwate Prefectural Cent Hosp, Morioka, Iwate, Japan

[8] Steel Mem Yawata Hosp, Kitakyushu, Fukuoka, Japan

[9] Asahikawa Med Ctr, Asahikawa, Hokkaido, Japan

[10] Nippon Med Sch, Tokyo, Japan

[11] Japanese Red Cross Okayama Hosp, Resp Med, Okayama, Japan

[12] Kesennuma City Hosp, Kesennuma, Miyagi, Japan

[13] Ishikawa Prefectural Cent Hosp, Kanazawa, Ishikawa, Japan

[14] Wakayama Med Univ, Dept Internal Med 3, Wakayama, Japan

[15] Oita Prefectural Hosp, Oita, Japan

[16] Fukuoka Univ, Chikushi Hosp, Chikushino, Japan

[17] Clin Res Support Ctr, Fukuoka, Fukuoka, Japan

[18] Kyushu Univ Hosp, Fukuoka, Fukuoka, Japan

[19] Natl Canc Ctr, Tokyo, Japan

[20] Wakayama Med Coll, Dept Internal Med 3, Wakayama, Japan

[21] Oita Univ, Oita, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

Alectinib; poor performance status; ALK rearrangement;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.03-004

引用

页码：S1951 / S1951

页数：1

共 50 条

[31] Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
Wu, Yi-Long
Dziadziuszko, Rafal
Ahn, Jin Seok
Barlesi, Fabrice
Nishio, Makoto
Lee, Dae Ho
Lee, Jong-Seok
Zhong, Wenzhao
Horinouchi, Hidehito
Mao, Weimin
Hochmair, Maximilian
de Marinis, Filippo
Migliorino, M. Rita
Bondarenko, Igor
Lu, Shun
Wang, Qun
Ochi Lohmann, Tania
Xu, Tingting
Cardona, Andres
Ruf, Thorsten
Noe, Johannes
Solomon, Benjamin J.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (14): : 1265 - 1276
[32] Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer
Burudpakdee, C.
Wong, W.
Seetasith, A.
Corvino, F. A.
Yeh, W.
Gubens, M.
[J]. LUNG CANCER, 2018, 119 : 103 - 111
[33] Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer
Yu, Hui
Sun, Si
Hu, Xingjiang
Xia, Jinjing
Wang, Jialei
Chen, Haiquan
[J]. ONCOTARGETS AND THERAPY, 2019, 12 : 6481 - 6495
[34] Bayesian analysis supports the role of alectinib and ensartinib for ALK-positive non-small cell lung cancer
Rizzo, Alessandro
[J]. THORACIC CANCER, 2023, 14 (13) : 1217 - 1217
[35] Alectinib/crizotinibDevelopment of drug resistance in ALK-positive non-small cell lung cancer: case report
[J]. Reactions Weekly, 2020, 1829 (1) : 23 - 23
[36] Diagnosis and Treatment of Advanced ALK Rearrangement-Positive Non-Small-Cell Lung Cancer in Portugal: Results of a National Questionnaire
Figueiredo, Ana
Rodrigues, Ana
Gaspar, Carina
Felizardo, Margarida
[J]. DRUGS-REAL WORLD OUTCOMES, 2023, 10 (04) : 545 - 555
[37] Alectinib in a patient with ALK-positive non-small lung cancer unable to swallow capsules
Ishiura, Yoshihisa
Nomura, Shosaku
Ishii, Yuka
Imai, Kai
Nakahama, Kahori
Sawai, Yusuke
Tamaki, Takeshi
Shimizu, Toshiki
Miyashita, Naoyuki
Ito, Tomoki
[J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (05) : 1283 - 1285
[38] Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma
Koyama, Kiyoko
Katsurada, Naoko
Jimbo, Naoe
Tachihara, Motoko
Tamura, Daisuke
Nakata, Kyosuke
Nagano, Tatsuya
Yamamoto, Masatsugu
Kamiryo, Hiroshi
Kobayashi, Kazuyuki
Itoh, Tomoo
Nishimura, Yoshihiro
[J]. PATHOLOGY INTERNATIONAL, 2019, 69 (05) : 294 - 299
[39] Diagnosis and Treatment of Advanced ALK Rearrangement-Positive Non-Small-Cell Lung Cancer in Portugal: Results of a National Questionnaire
Ana Figueiredo
Ana Rodrigues
Carina Gaspar
Margarida Felizardo
[J]. Drugs - Real World Outcomes, 2023, 10 : 545 - 555
[40] Challenges in defining and identifying patients with non-small cell lung cancer and poor performance status
Kelly, K
[J]. SEMINARS IN ONCOLOGY, 2004, 31 (06) : 3 - 7

← 1 2 3 4 5 →